With inflation trends diverging across regions and central banks keeping policy options open, it makes sense to focus on companies where growth and insider confidence line up. The Fast Growing Stocks With High Insider Ownership screener highlights businesses that analysts and management both view positively, which can be especially appealing when yields and wage data keep shifting. Insiders with meaningful stakes often have a strong interest in long term company health. In this article you will see 3 stocks from this screener that stand out for further research if you want exposure to growth supported by aligned leadership.
Overview: Lightspeed Commerce provides cloud-based software and payment tools that help retailers, restaurants and other small and mid sized businesses run their point of sale, manage inventory and staff, connect online and in store, and accept payments through a single platform.
Market Cap: CA$1.7b
Lightspeed Commerce offers exposure to the ongoing shift toward digital payments and unified commerce, with subscription and transaction revenue supported by AI driven insights, higher payments penetration and a focus on more profitable segments. Recent results indicate double digit revenue growth and a much smaller net loss. In addition, a 1x P/S and a share buyback suggest that management perceives value in the stock. However, the company still reports losses, faces well funded competitors in retail and hospitality software, and relies heavily on outbound sales and pricing to pursue its long term targets. As a result, the balance between potential upside and execution risk is an important consideration.
Lightspeed Commerce’s mix of double digit growth and a 1x P/S tag suggests the market may be missing something. Get the full context from the analysis report for Lightspeed Commerce and the quiet shift behind that buyback.
Overview: Universal Music Group is a global music company that signs recording artists and songwriters, manages their catalogues, and monetizes music through streaming platforms, physical formats, licensing for film and TV, and artist merchandise and branding.
Market Cap: €26.16b
Universal Music Group gives you exposure to the global shift toward paid music streaming and higher value premium tiers, while also leaning into AI centred partnerships and asset light ventures that can support margins over time. At the same time, the company is working through weaker recent earnings, a very high P/E multiple, and a heavy reliance on a small group of superstar artists. A sizeable buyback program, regular dividends, and renewed licensing deals with platforms like TikTok show that management is actively trying to support shareholder value, even as subscription growth and monetization of short form content face pressure. The key issue is how these moving pieces come together for long term shareholders.
Universal Music Group’s premium streaming focus, AI partnerships and superstar roster suggest the story is bigger than a high P/E tag. See how the 2 key rewards and 5 important warning signs might reframe the real swing factor behind those headline numbers
Overview: Corcept Therapeutics is a US biopharmaceutical company that develops drugs that modulate cortisol to treat serious endocrine, metabolic, neurologic and cancer conditions, with its approved product Korlym used for patients with Cushing’s syndrome who cannot undergo or have not benefited from surgery.
Market Cap: US$12.79b
Corcept Therapeutics sits at the intersection of growing demand for endocrine and oncology treatments and a maturing cortisol modulator pipeline that now includes Lifyorli in platinum resistant ovarian cancer and a resubmitted relacorilant application for Cushing’s syndrome with a December 17, 2026 FDA decision date. Recent record revenue, raised 2026 guidance to about US$1.15b at the midpoint, and high forecast earnings growth highlight the potential if new indications scale as planned. The catch is heavy dependence on Korlym pricing, ongoing litigation and regulatory risk, and a share price that already embeds strong expectations. For investors screening for high growth with insider ownership, the key consideration is how durable this earnings trajectory looks once Korlym faces fuller generic pressure and payers push harder on price.
Corcept Therapeutics looks like a classic “too strong to ignore” growth story, with Korlym cash flow and new indications setting expectations sky high. See how the analyst forecasts for Corcept Therapeutics could shift your view on what happens if that confidence cracks.
The three stocks in this article are just a starting point. The full Fast Growing Stocks With High Insider Ownership screener surfaces 1,294 more companies that pair strong growth profiles with management and analyst optimism through the Fast Growing Stocks With High Insider Ownership screener.
Use Simply Wall St to identify, analyze and filter for the specific catalysts and narratives that matter to you, so you can focus on the highest conviction ideas that fit your own portfolio goals.
If Universal Music Group or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Fresh ideas do not stay under the radar for long. Once momentum builds, entry points can move quickly. Scan these curated stock sets before the crowd catches on and consider taking action while conditions remain less crowded.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com